General Information of Drug (ID: DMYUSOJ)

Drug Name
RG6234 Drug Info
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMYUSOJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Talquetamab DMXRENI Multiple myeloma 2A83 Approved [2]
GPRC5D CAR-T cell therapy DM8MGSH Multiple myeloma 2A83 Phase 1 [3]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Blinatumomab DMGECIJ Acute lymphoblastic leukaemia 2A85 Approved [4]
Mosunetuzumab DM15ZIB Follicular lymphoma 2A80 Approved [5]
Epcoritamab DMEX86V Diffuse large B-cell lymphoma 2A81 Approved [6]
Talquetamab DMXRENI Multiple myeloma 2A83 Approved [2]
Elranatamab DMG1MW2 Multiple myeloma 2A83 Approved [7]
Nivatrotamab DMAOUZV Small-cell lung cancer 2C25.Y Phase 2 [8]
Otelixizumab DMFNDBC Type-1 diabetes 5A10 Phase 2 [9]
Plamotamab DMOV28A Diffuse large B-cell lymphoma 2A81 Phase 2 [10]
Odronextamab DMP6NVV B-cell non-hodgkin lymphoma 2B33.5 Phase 2 [11]
Tarlatamab DME33OU Small-cell lung cancer 2C25.Y Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
G-protein coupled receptor C 5D (GPRC5D) TTHRAPJ GPC5D_HUMAN Not Available [1]
T-cell surface glycoprotein CD3 (CD3) TTUN7MC NOUNIPROTAC Not Available [1]

References

1 Clinical pipeline report, company report or official report of Roche
2 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
3 GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019 Mar 27;11(485):eaau7746.
4 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
5 Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
6 Clinical pipeline report, company report or official report of Genmab.
7 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
8 Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
9 Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
10 Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
11 Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
12 Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.